Connection lost
Server error
HELSINN HEALTHCARE v. TEVA PHARMACEUTICALS Case Brief
Audio Insights: Learn Cases on The Go
Transform downtime into productive study time with our premium audio insights. Perfect for commutes, workouts, or visual breaks from reading.
Why Top Law Students (And Those Aspiring to Be) Use LSD+ Briefs
Let's be real, law school is a marathon. Our exclusive Flash-to-Full case system is designed by Harvard Law School and MIT grads to match your pace: Quick summaries when you're slammed, detailed analysis when you need to go deep. Only LSD+ offers this kind of flexibility to genuinely fit your study flow.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: A company sold its invention under a confidentiality agreement before filing for a patent. The Supreme Court held that this secret commercial sale still qualified as being “on sale” under the America Invents Act, invalidating the later-filed patent.
Legal Significance: The Court affirmed that the America Invents Act (AIA) did not change the pre-AIA standard for the “on-sale” bar. A commercial sale, even if secret, can trigger the one-year grace period for filing a patent application, thus serving as invalidating prior art.
HELSINN HEALTHCARE v. TEVA PHARMACEUTICALS Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Petitioner Helsinn Healthcare developed a drug, Aloxi, to treat chemotherapy-induced nausea. In 2001, Helsinn entered into two agreements with MGI Pharma: a license agreement and a supply and purchase agreement. These agreements granted MGI rights to market and sell specific doses of the drug in the United States and constituted a commercial sale of the invention. While the existence of the agreements was publicly disclosed in press releases and SEC filings, the specific drug dosages—the core of the invention—were kept confidential as required by the agreements. On January 30, 2003, nearly two years after the agreements were executed, Helsinn filed a provisional patent application. A subsequent patent, governed by the Leahy-Smith America Invents Act (AIA), claimed priority to this 2003 date. Respondent Teva Pharmaceuticals later sought to market a generic version of the drug and challenged Helsinn’s patent, arguing it was invalid under the AIA’s on-sale bar because the invention was “on sale” via the 2001 MGI agreements, more than one year before the patent’s effective filing date.
Court Holding & Legal Precedent
Issue: Does an inventor’s commercial sale of an invention to a third party, who is contractually obligated to keep the invention’s details confidential, place the invention “on sale” within the meaning of the America Invents Act’s prior art provision, 35 U.S.C. § 102(a)(1)?
Yes. A commercial sale of an invention to a third party who Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
IRAC Legal Analysis
Complete IRAC Analysis for Higher Grades
IRAC (Issue, Rule, Analysis, Conclusion) is the exact format professors want to see in your exam answers. Our exclusive Flash-to-Full briefs combine holding, analysis, and rule statements formatted to match what A+ students produce in exams. These structured briefs help reinforce the essential legal reasoning patterns expected in law school.
Legal Issue
Does an inventor’s commercial sale of an invention to a third party, who is contractually obligated to keep the invention’s details confidential, place the invention “on sale” within the meaning of the America Invents Act’s prior art provision, 35 U.S.C. § 102(a)(1)?
Conclusion
This decision clarifies that the AIA did not narrow the scope of Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
Legal Rule
Under the America Invents Act, an invention is "on sale" for the Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
Legal Analysis
The Court's analysis centered on the principle of statutory interpretation that when Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labori
Flash-to-Full Case Opinions
Flash Summary
- The America Invents Act (AIA) did not change the meaning of